NAFLD (nonalcoholic fatty liver disease), CVD, and type 2 diabetes: Details of the study design Targher G et al. Diabetes Care 2007;30:1212-8.

Slides:

Advertisements

Similar presentations

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:

Advertisements

ACCORD Design and Baseline Characteristics

All-cause mortality by treatment group

Copyright © 2007 American Medical Association. All rights reserved.

Effect of Food Insecurity on Chronic Kidney Disease in Lower-Income Americans Am J Nephrol 2014;39: DOI: / Fig. 1. Age-adjusted.

Copyright © 2012 American Medical Association. All rights reserved.

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.

Body Mass Index, Sex, and Cardiovascular Disease Risk Factors Among Hispanic/Latino Adults: Hispanic Community Health Study/Study of Latinos by Robert.

Prospective associations of plasma phospholipid trans/trans-18:2 with total mortality, CVD and CHD before and after mutual adjustment without correction.

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Change (with 95% CI) in outcomes by duration of type 2 diabetes

WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

Franklin SS, et al. Circulation 2009;119:243-50

Volume 155, Issue 1, Pages (July 2018)

OR (95% CI) for CHD associated with inflammatory markers before and after adjustment for established risk factors. OR (95% CI) for CHD associated with.

Description of studies for pooled analyses

Incidence of all renal events according to achieved BP levels, adjusted for age, gender, duration of diabetes, glycosylated hemoglobin, currently treated.

Wesley T. O’Neal et al. JACEP 2016;2:

Association between Nonalcoholic Fatty Liver Disease at CT and Coronary Microvascular Dysfunction at Myocardial Perfusion PET/CT Coronary microvascular.

OR (95% CI) for CHD associated with inflammatory markers in all participants and in subsets of non-users of statins or non-users of aspirin therapy. OR.

Baseline Characteristics of the Study Cohort*

Baseline characteristics of CACTI type 1 diabetic subjects with cystatin C measurements (n=509), stratified by CAC progression status Maahs DM et al.

Baseline Characteristics According to Sex

A.V. Khera et al. N Engl J Med 2011;364:127-35

Baseline Characteristics of the Subjects*

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Kotseva K, et al. Lancet 2009;373:929-40

Baseline Lipid Parameters and Characteristics Among 3110 Men According to Quintiles of Total Cholesterol Ruben O. Halperin et al, Hypertension 2006;47;45-50.

Baseline characteristics of older women (NHS I), younger women (NHS II), and men (HPFS) with a history of hypertension according to thiazide use Eric N.

Enrollment of patients.

Persistent organic pollutants and diabetes - Spearman correlation coefficients* among six POPs with age, sex, race and ethnicity, poverty income.

Adjusted ORs of AF within 30 days after bereavement with specific characteristics versus non-bereaved with the same characteristics. * *The vertical dashed.

Trends in prevalence of diabetes in middle-aged women grouped according to BMI at the first survey of the ALSWH. ▪, healthy (n = 5,252); ♦, overweight.

Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),

Incidences (%) for the development (for individuals without MetS at baseline, n = 125) (□) and the resolution (for individuals with MetS at baseline, n.

Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Associations between type of MI and incident HF

A: Mean wall motion score index (95% CI) in patients with first myocardial infarction segregated by Hp type. A: Mean wall motion score index (95% CI) in.

Correlation between progranulin (dependent variable) and CKD stage adjusted for age and sex, as well as DBP, WHR, triglycerides, HDL cholesterol, LDL cholesterol,

Flow of study participants

Adjusted HRs (95% CIs) for all-cause mortality associated with BMI by smoking status in men and women and by CHD, type 2 diabetes, and cancer status at.

Adjusted ORs of AF according to time since bereavement versus non-bereaved in a population from Denmark between 1995 and * *ORs are adjusted for.

Adjusted HRs (95% CIs) for all-cause mortality associated with body fat percentage by smoking status in men and women and by CHD, type 2 diabetes, and.

Trajectories over the 9 years of follow-up of HbA1c in all participants (n = 4,080 at baseline), stratified by the presence of a family history of diabetes,

ORs for presence of the metabolic syndrome (95% CI) at age 43 years according to leisure-time physical activity and TV viewing (adjusted for sex, socioeconomic.

Crude and adjusted HbA1c change by medication adherence group (proportion of days covered (PDC)) by linear regression, controlling for age, age2, gender,

Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.

Mean adjusted levels in each group for the following cardiometabolic risk factors at 3 and 12 months postpartum: (A) systolic blood pressure, (B) diastolic.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Associations between biomarkers of subclinical inflammation and progression of DSPN assessed by changes in MNSI in individuals with DSPN in KORA F4/FF4.

Trends in mortality by age-groups and select CVDs among adults with diabetes. Trends in mortality by age-groups and select CVDs among adults with diabetes.

ROC curves for cardiovascular events, all-cause mortality, and disease progression. ROC curves for cardiovascular events, all-cause mortality, and disease.

ROC curves for LDL cholesterol, apoB, non-HDL cholesterol, and the total cholesterol–to–HDL cholesterol ratio deciles. ROC curves for LDL cholesterol,

Adjusted all-cause (A) and CVD (B) mortality HRs (95% CIs) for IFG, IGT, NDM, and KDM compared with NGT according to ethnic group. Adjusted all-cause (A)

Risk of type 2 diabetes as a function of ABCA1 and ABCG1 genotype in CCHS. Hazard ratios were multifactorially adjusted for age, sex, BMI, hypertension,

Mean HbA1c (%) and estimated marginal mean SH rate (per 100 patient-years) adjusted for sex, age-group at diagnosis, and diabetes duration, by time period,

A1C at baseline, 16 weeks, and 32 weeks according to study group in all participants (A), adult participants (B), and adolescent participants (C) who returned.

RR (with 95% CI) of total mortality (multivariate-adjusted) by duration of smoking cessation among diabetic women. RR (with 95% CI) of total mortality.

A: Executive function performance assessed by D-KEFS Trail Making task (Number-Letter Switching) and depicted according to presence or absence of CVD in.

Unadjusted and adjusted prevalence estimates of self-reported cancer according to diabetes types among men (A) and women (B) (BRFSS 2009). Unadjusted and.

Risk of mortality in patients with diabetes and ESRD

Adjusted ORs of increasing severity of heartburn at follow-up in reference to baseline from model adjusted for BMI category, CVD history, BDI score >11,

HR for mortality in ischemic heart disease.

HR for myocardial infarction.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Adjusted HRs for death from any cause and death from specific causes among patients with type 1 diabetes. Adjusted HRs for death from any cause and death.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

NAFLD (nonalcoholic fatty liver disease), CVD, and type 2 diabetes: Details of the study design Targher G et al. Diabetes Care 2007;30:1212-8

Baseline characteristics of the study participants, grouped according to NAFLD status Targher G et al. Diabetes Care 2007;30:1212-8

Age- and sex-adjusted prevalence of CVD in type 2 diabetic adults with () and without () NAFLD Targher G et al. Diabetes Care 2007;30:1212-8

Association between NAFLD and prevalent CVD in type 2 diabetic adults with and without NAFLD (n=2.392) Data are expressed as ORs 95% CI. *The multiple adjustment reported in the third and fourth bars was as follows: age, sex, BMI, smoking status, diabetes duration, A1C, LDL cholesterol, and current use of medications (hypoglycemic, antihypertensive, lipid-lowering, or antiplatelet drugs). Targher G et al. Diabetes Care 2007;30:1212-8